(Q43224278)

16 November 2017

0 references

Asthma phenotypes and interleukin-13--moving closer to personalized medicine (English)

1 reference

16 November 2017

1 reference

personalized medicine

1 reference

Monica Kraft

1

1 reference

PMCID

4390041

16 November 2017

language of work or name

English

0 references

publication date

31 August 2011

1 reference

The New England Journal of Medicine

16 November 2017

1 reference

16 November 2017

365

1 reference

16 November 2017

12

1 reference

16 November 2017

1141-1144

1 reference

Lebrikizumab treatment in adults with asthma

16 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Airway fibroblasts in asthma manifest an invasive phenotype

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Increased sputum and bronchial biopsy IL-13 expression in severe asthma

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Requirement for IL-13 independently of IL-4 in experimental asthma

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

Significant variability in response to inhaled corticosteroids for persistent asthma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390041

15 August 2018

Identifiers

DOI

10.1056/NEJME1108666

1 reference

16 November 2017

1 reference

16 November 2017

1 reference

PMCID

4390041